Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010

IRVINE, Calif., Oct 18, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2010 financial results, which will take place on Wednesday, October 27, 2010 after the close of the market.

Endologix will hold a conference call on Wednesday, October 27, 2010 at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at www.endologix.com.

After the live Web cast, the call will remain available on Endologix's Web site, www.endologix.com, through November 27, 2010. In addition, a telephonic replay of the call will be available until November 3, 2010. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 358458.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

COMPANY CONTACT: Endologix, Inc.
John McDermott, CEO (949) 595-7200
www.endologix.com

INVESTOR CONTACTS: The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved